Diabetes Dialogue: The T1D Exchange, with David Walton


In many conversations related to diabetes, the focus is solely on patients with type 2 diabetes. Although patients with type 1 diabetes also face an increased risk of adverse outcomes as a result of the condition, they can go overlooked in larger, public health efforts. To combat this and improve care for patients with type 1 diabetes, multiple organizations have been formed with the specific intent of advancing management for this patient population. One of these organizations is the T1D Exchange.

With a mission of improving outcomes for the entire T1D population through driving real-world evidence and collaborative change, the organization is regarded as a leader in the space. A nonprofit organization founded in 2009, the Boston-based organization has grown by leaps and bounds in the last 13 years, including becoming a leader in data collection among patients with type 1 diabetes. With a registry including more than 3000 patients with type 1 diabetes, the group partners with major organizations and trialists to help further research as well as patient care.

At the Association of Diabetes Care and Education Specialists (ADCES) 2022 Annual Meeting, the hosts of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, dive deeper into the T1D Exchange and how they are helping patients in a sit-down interview with David Walton, the chief executive officer of the T1D Exchange. In their conversations, Walton details how he became involved in the organization, how patients can become involved or contribute data, and what plans the organization has for the future.

Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on Spotify and Apple Podcasts.

Related Videos
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
© 2024 MJH Life Sciences

All rights reserved.